Acquisition a Key Component in the Development of Complete Sample-to-Answer Solutions for Next-Generation Sequencing
SAN DIEGO--(BUSINESS WIRE)--Jul. 23, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Advanced Liquid Logic (ALL), a leading provider of liquid handling solutions. ALL, now a wholly owned subsidiary of Illumina, has developed a proprietary “digital microfluidics” technology based on electrowetting that precisely manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols. This proven technology will enable Illumina to deliver the simplest and most efficient sample-to-answer next-generation sequencing (NGS) workflow.
“For our research customers, ALL’s technology will further streamline the industry's simplest NGS workflow, while for clinical and applied markets, where ease of use and consistency are especially valued, it will allow us to offer integrated, end-to-end solutions,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions business. “ALL brings an impressive IP portfolio in digital microfluidics and a talented team with a track record of innovation.”
One of Illumina's goals is to provide customers with a holistic set of tools to go from biological sample to answer quickly and easily, minimizing the risk of errors and reducing hands-on time in the lab. To that end, Illumina recently announced it is collaborating with leading vendors of liquid handling robotic platforms to make automation solutions for high-throughput sample preparation more accessible. With its acquisition of ALL, Illumina will be able to introduce similar benefits to its low- and mid-throughput customers.
ALL’s versatile technology has been demonstrated across numerous applications, including nucleic acid isolation from various sample types and library generation for next-generation sequencing. Its robust solution has a clear advantage in precisely handling low sample volumes, which is an increasingly important focus for customers.
For more information about ALL’s technology, visit www.liquid-logic.com/technology.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
